H5N1 influenza virus vaccine intranasal - Nanotherapeutics

Drug Profile

H5N1 influenza virus vaccine intranasal - Nanotherapeutics

Alternative Names: GelVac™ nasal influenza vaccine

Latest Information Update: 20 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DelSite Biotechnologies
  • Developer Nanotherapeutics
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 20 Apr 2016 This programme is still active
  • 03 Oct 2011 Interim adverse events and immunogenicity data from a phase I trial in Influenza virus infection released by Nanotherapeutics
  • 31 Aug 2010 Phase-I clinical trials in Influenza virus infections in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top